Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases
Ella Day | June 3, 2025 | News story | Mergers and Acquisitions, Research and Development | Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases
Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This adds Blueprint’s medicine for systemic mastocytosis (SM), a rare immunology disease, to Sanofi’s growing immunology pipeline.
The acquisition includes Ayvakit/Ayvakyt (avapritinib), which is the only approved medicine for advanced and indolent SM. Additionally, Sanofi will obtain elenestinib, another medicine for SM and BLU-808 – a prospective treatment for a range of diseases in immunology.
Through developing therapeutics on two focus areas, allergy/inflammation and oncology/haematology, Blueprint has become globally accredited among allergists, dermatologists and immunologists.
SM is a rare immunology disease, characterised by the accumulation and activation of deviant mast cells in bone marrow, skin, the gastrointestinal (GI) tract and other organs. It can cause a range of debilitating symptoms across organ systems including anaphylaxis, bone disease and GI distress, significantly impacting patients’ quality of life.
“The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios,” said Paul Hudson, CEO of Sanofi.
Kate Haviland, CEO of Blueprint Medicines commented: “With this agreement, we begin our next chapter with Sanofi […] to accelerate our joint mission to bring life-changing medicines to many more patients around the world.”
Ella Day
3/6/25
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
